For both the RA patients receiving the combination of methotrexate and those receiving other csDMARDs, the DAS28ESR at W0, W4, W12, and W24, as well as the clinical response, LDA, and remission rates at W4, W12, and W24, remained unchanged between the ADA group and the ETN group (all p > .05) (Table 2). This evidence concerns the gene ADA and rheumatoid arthritis.